The only FDA-cleared enzyme product to
Break down fats in enteral formula
Clinical experts on using RELiZORB
See How RELiZORB Works
What makes RELiZORB different?
RELiZORB Hydrolyzes Fats Prior to Ingestion
RELiZORB is a digestive enzyme cartridge that contains iLipase® and connects in-line with enteral feeding systems. Lipase is covalently bound to small white beads inside the RELiZORB cartridge and is retained in the cartridge during use by two filters. Enteral formula flows through, allowing for fat breakdown and the immediate delivery of absorbable fatty acids and monoglycerides to the gastrointestinal (GI) tract.
RELiZORB is proven to hydrolyze available fats,* including medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs).1
- The iLipase in RELiZORB is intended to selectively break down triglycerides at the sn-1 and sn-3 positions.
- LCTs are complex and contain essential fatty acids. Compared to MCTs, LCTs are harder to hydrolyze2 and provide ~10% more calories.1
*Greater than 90% of available fats hydrolyzed in most enteral formulas tested, including Nutren 1.5, Impact Peptide 1.5, Peptamen 1.5, Peptamen AF, and Nutren 1.0. Percentage of fat hydrolysis is estimated based on label claim for content, calculated using 500 mL of formula with a pump rate of 120 mL/hr. Please see full list of compatible formulas.
- Freedman S. Options for Addressing Exocrine Pancreatic Insufficiency in Patients Receiving Enteral Nutrition Supplementation. Am J Manag Care. 2017 Jul;23(12 Suppl):S220-S228.
- Shah ND, Limketkai BN. The Use of Medium-Chain Triglycerides in Gastrointestinal Disorders. Practical Gastroenterology. 2017 Feb;41(2):20-28.